Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2007

View Archived Issues

SuperGen presents overview of preclinical pipeline

Targeting topoisomerase II with R-16 induces apoptosis and cell cycle arrest in tumor cell lines

Recent patents disclose novel anticancer compounds

Resveratrol analogue M-8 active against melanoma cells

BAY-65-5811 and doxorubicin synergistic against melanoma cells

Hepatitis E virus vaccine effective in phase II study

Novel agents for inflammatory disorders disclosed in recent patents

Recent Merck Frosst patent describes new treatment option for atherosclerosis

HanAll licenses Nautilus compounds for South Korea

MK-2048 shows in vitro activity against resistant HIV-1 mutants

ProNAi and Novosom collaborate on DNAi-based cancer therapeutics

Novartis extends research collaboration with Idera

New formulation of oral methylnaltrexone begins clinical testing

Avalon and Merck & Co. collaborate in cancer

Phosphagenics extends transdermal technology platform

Affectis and Mitsubishi extend research collaboration

ZymoGenetics updates plans for rhThrombin

Crucell to receive funding in development of AdVac-based TB vaccine

Acrux and Organon sign new agreement in women's health

Novel polyamine biosynthesis inhibitor shows potential to prevent HIV/SIV-related encephalitis

ABT-894 begins phase II study for ADHD

Genta and IDIS sign compassionate use agreement for Ganite and Genasense

Stemline Therapeutics in-licenses worldwide rights to SL-401

RVX-208 completes toxicology studies on way to IND filing

NeuroVax studied in new phase II trial for relapsing-remitting MS

New phase I/II trial studies Ferritarg P for Hodgkin's disease

Financing at Potentia to support AMD program

AS-1404 with carboplatin and paclitaxel shows good response rate in NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...